Ecuador vs Ghana: Average cost of drugs for extensively drug-resistant tuberculosis
Ecuador
451 constant 2022 US$
in 2024
Ghana
800 constant 2022 US$
in 2024
Ecuador rank
50th
Ghana rank
47th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Ecuador
- Ghana
How they compare
Ghana currently reports 800 constant 2022 US$ against 451 constant 2022 US$ in Ecuador, a difference of 349 constant 2022 US$.
That makes Ghana's figure about 1.8 times Ecuador's.
The two have swapped places 2 times across 5 shared years of data; in 2019 it was Ghana ahead.
Ecuador ranks 50th and Ghana ranks 47th of 56 countries.
Ghana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Ecuador | Ghana | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,241 constant 2022 US$ | 2,500 constant 2022 US$ | 1,259 constant 2022 US$ | Ghana |
| 2020s | 877.75 constant 2022 US$ | 1,382 constant 2022 US$ | 504.75 constant 2022 US$ | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Ecuador or Ghana?
- Ghana, at 800 constant 2022 US$ against 451 constant 2022 US$ in Ecuador as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Ecuador and Ghana?
- 349 constant 2022 US$, with Ghana ahead.
- How many years of comparable data are there for Ecuador and Ghana?
- 5 years are reported by both, from 2019 to 2024.
- How do Ecuador and Ghana rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Ecuador ranks 50th and Ghana ranks 47th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.